{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T17:16:52Z","timestamp":1781543812926,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,1,1]],"date-time":"2008-01-01T00:00:00Z","timestamp":1199145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s11940-008-0007-z","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T21:12:44Z","timestamp":1202332364000},"page":"55-66","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":113,"title":["Neuromyelitis optica"],"prefix":"10.1007","volume":"10","author":[{"given":"Dean M.","family":"Wingerchuk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,2,7]]},"reference":[{"key":"7_CR1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"D.M. Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, et al.: The spectrum of neuromyelitis optica. Lancet Neurol 2007, 6:810\u2013815.","journal-title":"Lancet Neurol"},{"key":"7_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11940-005-0010-6","volume":"7","author":"D.M. Wingerchuk","year":"2005","unstructured":"Wingerchuk DM, Weinshenker BG: Neuromyelitis optica. Curr Treat Options Neurol 2005, 7:173\u2013182.","journal-title":"Curr Treat Options Neurol"},{"key":"7_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","volume":"66","author":"D.M. Wingerchuk","year":"2006","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, et al.: Revised diagnostic criteria for neuromyelitis optica. Neurology 2006, 66:1485\u20131489.","journal-title":"Neurology"},{"key":"7_CR4","doi-asserted-by":"crossref","unstructured":"Saiz A, Zuliani L, Blanco Y, et al., for the Spanish-Italian NMO Study Group: Revised diagnostic criteria for neuromyelitis optica (NMO): application in a series of suspected patients. J Neurol 2007 [Epub ahead of print].","DOI":"10.1007\/s00415-007-0509-8"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"V.A. Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004, 364:2106\u20132112.","journal-title":"Lancet"},{"key":"7_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"V.A. Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473\u2013477.","journal-title":"J Exp Med"},{"key":"7_CR7","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1212\/01.wnl.0000256822.01222.bd","volume":"68","author":"S. Jarius","year":"2007","unstructured":"Jarius S, Franciotta D, Bergamaschi R, et al.: NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007, 68:1076\u20131077.","journal-title":"Neurology"},{"key":"7_CR8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/brain\/awm027","volume":"130","author":"T. Matsuoka","year":"2007","unstructured":"Matsuoka T, Matsushita T, Kawano Y, et al.: Heterogeneity of aquaporin 4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130:1206\u20131223.","journal-title":"Brain"},{"key":"7_CR9","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T. Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, et al.: Anti-aquaporin 4 antibody is involved in the pathogenesis of NMO: a study on antibody titer. Brain 2007, 130:1235\u20131243.","journal-title":"Brain"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/archneur.63.3.390","volume":"63","author":"S.J. Pittock","year":"2006","unstructured":"Pittock SJ, Lennon VA, Krecke K, et al.: Brain MRI abnormalities in neuromyelitis optica. Arch Neurol 2006, 63:390\u2013396.","journal-title":"Arch Neurol"},{"key":"7_CR11","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archneur.63.7.964","volume":"63","author":"S.J. Pittock","year":"2006","unstructured":"Pittock SJ, Weinshenker BG, Lucchinetti CF, et al.: Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006, 63:964\u2013968.","journal-title":"Arch Neurol"},{"key":"7_CR12","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"C.F. Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 2002, 125:1450\u20131461.","journal-title":"Brain"},{"key":"7_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00401-006-0169-2","volume":"113","author":"C. Sinclair","year":"2007","unstructured":"Sinclair C, Kirk J, Herron B, et al.: Absence of aquaporin 4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal appearing white matter. Acta Neuropathol 2007, 113:187\u2013194.","journal-title":"Acta Neuropathol"},{"key":"7_CR14","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"S.F. Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, et al.: Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007, 130:1194\u20131205.","journal-title":"Brain"},{"key":"7_CR15","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/brain\/awm047","volume":"130","author":"T. Misu","year":"2007","unstructured":"Misu T, Fujihara K, Kakita A, et al.: Loss of aquaporin-4 in lesions in neuromyelitis optica: distinction from multiple sclerosis. Brain 2007, 130:1224\u20131234.","journal-title":"Brain"},{"key":"7_CR16","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"D.M. Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinshenker BG: The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999, 53:1107\u20131114.","journal-title":"Neurology"},{"key":"7_CR17","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ana.20770","volume":"59","author":"B.G. Weinshenker","year":"2006","unstructured":"Weinshenker BG, Wingerchuk DM, Vukusic S, et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006, 59:566\u2013569.","journal-title":"Ann Neurol"},{"key":"7_CR18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"D.M. Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG: Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003, 60:848\u2013853.","journal-title":"Neurology"},{"key":"7_CR19","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"D.M. Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Pittock SJ, et al.: A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007, 68:603\u2013605.","journal-title":"Neurology"},{"key":"7_CR20","unstructured":"Filippini G, Brusaferri F, Sibley WA, et al.: Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000, CD001331."},{"key":"7_CR21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"R.W. Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson MM Jr, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992, 326:581\u2013588.","journal-title":"N Engl J Med"},{"key":"7_CR22","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/archopht.1997.01100160715008","volume":"115","author":"The Optic Neuritis Study Group","year":"1997","unstructured":"The Optic Neuritis Study Group: Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997, 115:1545\u20131552.","journal-title":"Arch Ophthalmol"},{"key":"7_CR23","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s004150070172","volume":"247","author":"F. Brusaferri","year":"2000","unstructured":"Brusaferri F, Candelise L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000, 247:435\u2013442.","journal-title":"J Neurol"},{"key":"7_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/0140-6736(90)92188-N","volume":"336","author":"J. Yan","year":"1990","unstructured":"Yan J, Richert JR, Sirdofsky MD: High-dose intravenous immunoglobulin for multiple sclerosis. Lancet 1990, 336:692.","journal-title":"Lancet"},{"key":"7_CR25","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1191\/1352458504ms978sr","volume":"10","author":"L.H. Visser","year":"2004","unstructured":"Visser LH, Beekman R. Tijssen CC, et al.: A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004, 10:89\u201391.","journal-title":"Mult Scler"},{"key":"7_CR26","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1212\/01.WNL.0000145798.61383.39","volume":"63","author":"P.S. Sorensen","year":"2004","unstructured":"Sorensen PS, Haas J, Sellebjerg F, et al.; TARIMS Study Group: IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004, 63:2028\u20132033.","journal-title":"Neurology"},{"key":"7_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1136\/jnnp.61.4.418-a","volume":"61","author":"C. Nos","year":"1996","unstructured":"Nos C, Comabella M, Tintore M, et al.: High dose intravenous immunoglobulin does not improve abnormalities in the blood-brain barrier during acute relapse of multiple sclerosis. J Neurol Neurosurg Psychiatry 1996, 61:418\u2013419.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7_CR28","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1001\/jama.269.16.2110","volume":"269","author":"G.A. Chrousos","year":"1993","unstructured":"Chrousos GA, Kattah JC, Beck RW, et al.: Side effects of glucocorticoid treatment: experience of the Optic Neuritis Treatment Trial. JAMA 1993, 269:2110\u20132112.","journal-title":"JAMA"},{"key":"7_CR29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1212\/01.WNL.0000151856.10387.E2","volume":"64","author":"T. Saida","year":"2005","unstructured":"Saida T, Tashiro K, Itoyama Y, et al.: Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study. Neurology 2005, 64:621\u2013630.","journal-title":"Neurology"},{"key":"7_CR30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/1352458506070732","volume":"13","author":"C. Papeix","year":"2007","unstructured":"Papeix C, Vidal JS, de Seze J, et al.: Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007, 13:256\u2013259.","journal-title":"Mult Scler"},{"key":"7_CR31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jns.2006.10.008","volume":"252","author":"Y. Warabi","year":"2007","unstructured":"Warabi Y, Matsumoto Y, Hayashi H: Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci 2007, 252:257\u2013261.","journal-title":"J Neurol Sci"},{"key":"7_CR32","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"R.N. Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE: Devic\u2019s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219\u20131220.","journal-title":"Neurology"},{"key":"7_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1177\/1352458507077189","volume":"13","author":"S. Watanabe","year":"2007","unstructured":"Watanabe S, Misu T, Miyazawa I, et al.: Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007, 13:968\u2013974.","journal-title":"Mult Scler"},{"key":"7_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0140-6736(04)16808-6","volume":"364","author":"G. Remuzzi","year":"2004","unstructured":"Remuzzi G, Lesti M, Gotti E, et al.: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503\u2013512.","journal-title":"Lancet"},{"key":"7_CR35","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","volume":"64","author":"B.A. Cree","year":"2005","unstructured":"Cree BA, Lamb S, Morgan K, et al.: An open-label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270\u20131272.","journal-title":"Neurology"},{"issue":"Suppl1","key":"7_CR36","first-page":"A206","volume":"68","author":"A. Jacob","year":"2007","unstructured":"Jacob A, Weinshenker B, McLinskey N, et al.: Retrospective analysis of rituximab treatment of 24 cases of neuromyelitis optica [abstract]. Neurology 2007, 68(Suppl 1):A206.","journal-title":"Neurology"},{"key":"7_CR37","unstructured":"Rituxan warning. FDA Consum 2007, 41(2):3."},{"key":"7_CR38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J. Bakker","year":"2004","unstructured":"Bakker J, Metz L: Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265\u2013267.","journal-title":"Can J Neurol Sci"},{"key":"7_CR39","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"H.P. Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002, 360:2018\u20132025.","journal-title":"Lancet"},{"key":"7_CR40","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","volume":"61","author":"D.S. Goodin","year":"2003","unstructured":"Goodin DS, Arnason BG, Coyle PK, et al.: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:1332\u20131338.","journal-title":"Neurology"},{"key":"7_CR41","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archneur.63.7.957","volume":"63","author":"B. WeinstockGuttman","year":"2006","unstructured":"WeinstockGuttman B, Ramanathan M, Lincoff N, et al.: Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006, 63:957\u2013963.","journal-title":"Arch Neurol"},{"key":"7_CR42","doi-asserted-by":"crossref","unstructured":"Minagar A, Sheremata WA: Treatment of Devic\u2019s disease with methotrexate and prednisone. Intl J MS Care (Serial online) 2000, 2(4). Available at http:\/\/www.mscare.org\/cmsc\/images\/pdf\/ijmsc2000dec.pdf. Accessed Oct. 16, 2007.","DOI":"10.7224\/1537-2073-2.4.43"},{"key":"7_CR43","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"B.G. Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878\u2013886.","journal-title":"Ann Neurol"},{"key":"7_CR44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","volume":"58","author":"M. Keegan","year":"2001","unstructured":"Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of demyelination: predictors of response. Neurology 2001, 58:143\u2013146.","journal-title":"Neurology"},{"key":"7_CR45","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1352458506071174","volume":"13","author":"S. Watanabe","year":"2007","unstructured":"Watanabe S, Nakashima I, Misu T, et al.: Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007, 13:128\u2013132.","journal-title":"Mult Scler"},{"key":"7_CR46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","volume":"63","author":"K. Ruprecht","year":"2004","unstructured":"Ruprecht K, Klinker E, Dintelmann T, et al.: Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology 2004, 63:1081\u20131083.","journal-title":"Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-008-0007-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-008-0007-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-008-0007-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-008-0007-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:56:19Z","timestamp":1659095779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-008-0007-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["7"],"URL":"https:\/\/doi.org\/10.1007\/s11940-008-0007-z","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"7 February 2008","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}